PrismRA的动态

During a Case-Based Roundtable? event, Saad Z. Usmani, MD, FACP, MBA, discussed CAR T-cell therapy as third-line therapy for a patient with relapsed/refractory multiple myeloma and relevance of the KarMMa-3 trial for their treatment. #mmsm https://lnkd.in/eNe-WUWC

John Mascarenhas, MD, shares insight into his study regarding the addition of pelabresib to a medication known as ruxolitinib in order to improve outcomes and quality of life in patients with myelofibrosis. #Myelofibrosis #MedicalResearch #TreatmentStudy https://lnkd.in/eR2x8j4s

A scoping review assesses tools measuring patient and provider treatment preferences in hepatocellular carcinoma (HCC). Findings: patients often prioritize extending life but consider quality of life trade-offs. Physicians' preferences are influenced by patient-specific and institutional variables. The study calls for further research on preference tools for emerging HCC therapies and their role in guiding treatment choices. #HepatocellularCarcinoma #PatientCare #MedicalDecisionMaking

Fibrin drives thromboinflammation and neuropathology in COVID-19 Study: fibrin-targeting immunotherapy may represent a therapeutic intervention for patients with acute #COVID19 and #longCOVID https://lnkd.in/gwBK9kyC

#Darolutamide plus androgen-deprivation therapy (ADT), without docetaxel, improves radiological progression-free survival and secondary efficacy outcomes vs placebo plus ADT in patients with metastatic hormone-sensitive?#prostatecancer?(#mHSPC), according to results of the global phase III #ARANOTE trial presented at #ESMO2024. https://lnkd.in/gqqwpqX7

Our PROphetNSCLC? test has demonstrated strong clinical validity in predicting the benefit of PD-L1 inhibitor therapies. Not only is there a high correlation between the predicted clinical benefit probability and the observed clinical benefit rate, but a positive PROphetNSCLC? result is also associated with a statistically significant survival benefit. By providing deeper insights beyond PD-L1 status, PROphetNSCLC? empowers physicians with critical data to guide treatment decisions and improve patient outcomes. #LungCancer #PrecisionOncology #Immunotherapy #LCSM

1. Researchers identified a biomarker to predict the success of immunomodulator treatment for inflammatory bowel disease (IBD). 2. IBD includes conditions like Crohn's disease and ulcerative colitis, caused by an overactive immune response in the gastrointestinal tract. 3. Current treatments focus on symptom relief and inflammation control, with no cure available. 4. Integrin-blocking therapy is effective in about two-thirds of patients, but one-third do not respond, leading to trial and error in treatment. 5. The study involved 47 chronic IBD patients, utilizing advanced analytical methods and machine learning for data analysis. 6. High levels of the Ki67 protein in patients' blood prior to treatment indicated a lack of response to vedolizumab, an integrin-blocking therapy. 7. The research team aims to validate their findings through large-scale multicenter studies for clinical application. 8. Reliable biomarkers are essential for personalized medicine, allowing for faster and more accurate treatment decisions for IBD patients.

Zanubrutinib demonstrated long-term improved efficacy vs bendamustine + rituximab at 5-year follow-up in patients with treatment-naive #CLL/SLL, according to findings presented at #ASH24. Fred Hutch https://lnkd.in/gs7BgJfd

WATCH: Panelists discuss how the AQUILA trial evaluated whether daratumumab monotherapy provides superior outcomes compared with active monitoring in high-risk smoldering multiple myeloma patients. #mmsm https://lnkd.in/eNADZM88

A tale of 2 cities, Proton CSI for LMD 9 Patients median OS 4 mos ↑↑ OS if pre-CSI CSF diversion OR post CSI systemic therapy Patient selection is key! 1/3